Issue: March 2015
March 09, 2015
1 min read
Save

Trial Scorecard: SERAPHIN

Issue: March 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers assessed the impact of macitentan on all-cause hospitalization in patients with symptomatic pulmonary arterial hypertension.

Trial Scorecard: SERAPHIN